

WEAT GOVERNMENT OF THE DISTRICT OF COLUMBIA

# Government of the District of Columbia Department of Health

## Prescription Drug Monitoring Program Advisory Committee Meeting

2201 Shannon Place SE WASHINGTON, DC 20020

WEBEX MEETING April 8, 2025 10:05 AM—10:49 AM

**Open Session Minutes** 

### CALL TO ORDER: 10: 05 am

#### **PRESIDING: Aisha Nixon**

## **COMMITTEE MEMBERSHIP/ATTENDANCE:**

ADVISORY COMMITTEE MEMBERS:		
	Aisha Nixon, MPT, CPM, Associate Director	PRESENT
	Justin Ortique, PharmD, RPh, CPM, Board of Pharmacy Executive Director, Program Manager Pharmaceutical Control Division	PRESENT
	Sithembile Chithenga, MD, MPH Board of Medicine Executive Director	ABSENT
	Vito R. DelVento, DVM, MS, Board of Veterinary Medicine Executive Director, Program Manager Animal Services Program	ABSENT
	Camesha Thompson, RN ACRN, Board of Nursing Executive Director	PRESENT
	Natalie Kirilichin, MD, MPH, Emergency Medicine Physician	ABSENT
	Sheri Doyle, MPH, Consumer Member	PRESENT
	Captain Shawn Rooney, Metropolitan Police Department	ABSENT
	Careen-Joan Franklin, PharmD, RPh, Pharmacist	PRESENT
	Sharon Hunt, L.I.C.S.W., Ph.D., State Opioid Treatment Authority	PRESENT
	Kimberley Heine, Forensic Toxicologist, QA/QC Program Manager	PRESENT
	Tayiana J Reed, Pharm D, MS, AAHIVP, RPH, Pharmacist	PRESENT
PDMP STAFF:	Reginal Bellamy, PharmD, RPh, Supervisory Pharmacist	ABSENT
	Monai Lowe, PharmD, RPh, PDMP Pharmacist	PRESENT
	Laurel Alcenat, MBA, Program Specialist	PRESENT
LEGAL STAFF:	Carla Williams, Esq, Senior Assistant General Counsel, PDMP Attorney Advisor	PRESENT
VISITORS:	Sahar Majid, Health Licensing Specialist (covering for Dr. Vito R. DelVento)	
	Justin Wood, DEA Representative	

2201 Shannon Place SE | 2<sup>nd</sup> Fl, Washington, DC 20002 | E doh.pdmp@dc.gov | https://dchealth.dc.gov/pdmp

All prescription monitoring data collected, maintained, or submitted pursuant to this Program is confidential, privileged, not subject to discovery, subpoena, or other means of legal compulsion in civil litigation, and is not a public record.

### Open Session Agenda Quorum: YES

<ul> <li>Ms. Aisha Nixon called the meeting to order and introduced our new committee member: Camesha Thompson, the Executive Director of the Board of Nursing.</li> <li>Ms. Camesha Thompson gave a brief background of herself. She's new to this position but now new to DC Health. She previously served as nurse consultant for School Health Services. She's also served as care coordinator and infectious disease case manager throughout DC, Maryland, and Virginia. She stated how happy and excited she is to be a part of the committee.</li> <li>Chair Report</li> <li>Ms. Aisha Nixon expressed that we are monitoring all of our Federal grants, since the PDMP is ran off federal funding. She doesn't think we'll be affected but they are monitoring all the updates. She methomed that they are looking at other grant options just in case we lose funding.</li> <li>Charge of the Committee</li> <li>The Committee shall convene at least two (2) times per year to advise the Director:         <ul> <li>On the implementation and evaluation of the Program;</li> <li>On the establishment of criteria for indicators of possible misuse or abuse of covered substances;</li> <li>On standardization of the methodology that should be used for analysis and interpretations of possible abuse or covered substances;</li> <li>On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and</li> <li>Regarding the design and implementation of educational courses for:</li></ul></li></ul>	0408-O-01	Welcome New Committee Members & Introductions							
<ul> <li>Ms. Aisha Nixon expressed that we are monitoring all of our Federal grants, since the PDMP is ran off federal funding. She doesn't think we'll be affected but they are monitoring all the updates. She mentioned that they are looking at other grant options just in case we lose funding.</li> <li>Charge of the Committee</li> <li>The Committee shall convene at least two (2) times per year to advise the Director: <ul> <li>On the implementation and evaluation of the Program;</li> <li>On the establishment of criteria for indicators of possible misuse or abuse of covered substances;</li> <li>On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data;</li> <li>In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or covered substances;</li> <li>On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and</li> <li>Regarding the design and implementation of educational courses for: <ul> <li>(1) Persons who are authorized to access the prescription monitoring information;</li> <li>(2) Persons who are authorized to access the prescription monitoring information;</li> </ul> </li> </ul></li></ul>		<ul> <li>member: Camesha Thompson, the Executive Director of the Board of Nursing.</li> <li>Ms. Camesha Thompson gave a brief background of herself. She's new to this position but now new to DC Health. She previously served as nurse consultant for School Health Services. She's also served as care coordinator and infectious disease case manager throughout DC, Maryland, and Virginia. She stated how</li> </ul>							
<ul> <li>since the PDMP is ran off federal funding. She doesn't think we'll be affected but they are monitoring all the updates. She mentioned that they are looking at other grant options just in case we lose funding.</li> <li>Charge of the Committee</li> <li>The Committee shall convene at least two (2) times per year to advise the Director: <ul> <li>On the implementation and evaluation of the Program;</li> <li>On the establishment of criteria for indicators of possible misuse or abuse of covered substances;</li> <li>On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data;</li> <li>In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances;</li> <li>On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and</li> <li>Regarding the design and implementation of educational courses for: <ul> <li>(1) Persons who are authorized to access the prescription monitoring information;</li> <li>(2) Persons who are authorized to access the prescription monitoring information; but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled</li> </ul> </li> </ul></li></ul>		Chair Report							
<ul> <li>The Committee shall convene at least two (2) times per year to advise the Director:</li> <li>On the implementation and evaluation of the Program;</li> <li>On the establishment of criteria for indicators of possible misuse or abuse of covered substances;</li> <li>On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data;</li> <li>In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances;</li> <li>On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and</li> <li>Regarding the design and implementation of educational courses for:</li> <li>(1) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled</li> </ul>		since the PDMP is ran off federal funding. She doesn't think we'll be affected but they are monitoring all the updates. She mentioned that they are looking at other							
<ul> <li>Director:</li> <li>On the implementation and evaluation of the Program;</li> <li>On the establishment of criteria for indicators of possible misuse or abuse of covered substances;</li> <li>On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data;</li> <li>In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances;</li> <li>On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and</li> <li>Regarding the design and implementation of educational courses for: <ul> <li>(1) Persons who are authorized to access the prescription monitoring information;</li> <li>(2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled</li> </ul> </li> </ul>		Charge of the Committee							
<ul> <li>On the establishment of criteria for indicators of possible misuse or abuse of covered substances;</li> <li>On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data;</li> <li>In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances;</li> <li>On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and</li> <li>Regarding the design and implementation of educational courses for:</li> <li>(1) Persons who are authorized to access the prescription monitoring information;</li> <li>(2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled</li> </ul>		The Committee shall convene at least two (2) times per year to advise the							
<ul> <li>abuse of covered substances;</li> <li>On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data;</li> <li>In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances;</li> <li>On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and</li> <li>Regarding the design and implementation of educational courses for: <ul> <li>(1) Persons who are authorized to access the prescription monitoring information;</li> <li>(2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled</li> </ul> </li> </ul>		<ul> <li>On the implementation and evaluation of the Program;</li> </ul>							
<ul> <li>and interpretation of prescription monitoring data;</li> <li>In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances;</li> <li>On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and</li> <li>Regarding the design and implementation of educational courses for: <ul> <li>(1) Persons who are authorized to access the prescription monitoring information;</li> <li>(2) Persons who are authorized to access the prescription monitoring information; but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled</li> </ul> </li> </ul>									
<ul> <li>disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances;</li> <li>On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and</li> <li>Regarding the design and implementation of educational courses for: <ul> <li>(1) Persons who are authorized to access the prescription monitoring information;</li> <li>(2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled</li> </ul> </li> </ul>									
<ul> <li>and that should be monitored; and</li> <li>Regarding the design and implementation of educational courses for: <ol> <li>Persons who are authorized to access the prescription monitoring information;</li> </ol> </li> <li>(2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled</li> </ul>		disclose the findings to proactively inform prescribers regarding the							
<ul> <li>(1) Persons who are authorized to access the prescription monitoring information;</li> <li>(2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled</li> </ul>									
<ul> <li>information;</li> <li>(2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled</li> </ul>		Regarding the design and implementation of educational courses for:							
information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled									
		information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled							

	(3) Prescribers on prescribing practices, pharmacology, and identifying, treating, and referring patients addicted to or abusing controlled substances or drugs monitored by the Program; and	
	(4) The public about the use, diversion and abuse of, addiction to, and treatment for the addiction to controlled substances or drugs monitored by the Program.	
	• Ms. Aisha Nixon provided a brief overview of the Charge of the committee	
0408-0-02	Approval of December 2024 PDMP Advisory Committee Meeting Minutes	Ms. Nixon
	(a) Minutes from the December 2024 Meeting	
	<i>Motion:</i> Committee member Dr. Ortique made the motion to approve the December 2024 meeting minutes.	
	Seconded by: Committee member Dr. Sharon Hunt	
	Roll Call Vote :	
	Dr. Justin Ortique votes in favor of the Motion	

	Dr. Sharon Hunt votes in favor of the Motion	
	<ul> <li>Ms. Kimberley Heine votes in favor of the Motion</li> </ul>	
	<ul> <li>Dr. Tayiana Reed votes in favor of the Motion</li> </ul>	
	<ul> <li>Dr. Careen-Joan Franklin votes in favor of the Motion</li> </ul>	
	Abstentions:	
	Ms. Camesha Thompson	
	<ul> <li>Ms. Sheri Doyle</li> </ul>	
	Motion carried; minutes approved	
408-0-03	Report from Attorney Advisor	Ms. Williams
	No Report	vvillariis
0408-0-04	Matters for Consideration	Dr. Ortique
	<ul> <li>Motion to have support from the committee to create a Continuing Education (CE) training program for providers and dispensers registering for the PDMP         <ul> <li>Motion carried: Dr. Careen-Joan Franklin</li> <li>Motion seconded: Dr. Tayiana Reed</li> <li>Roll call Vote:                 <ul> <li>Dr. Justin Ortique votes in favor of the motion</li> <li>Ms. Camesha Thompson votes in favor of the motion</li> <li>Ms. Sheri Doyle votes in favor of the motion</li> <li>Dr. Sharon Hunt votes in favor of the motion</li> <li>Ms. Kimberley Heine votes in favor of the motion</li> <li>Dr. Tayiana Reed votes in favor of the motion</li> <li>Dr. Careen-Joan Franklin votes in favor of the motion</li> <li>Ms. Kimberley Heine votes in favor of the motion</li> <li>Dr. Careen-Joan Franklin votes in favor of the motion</li> <li>Dr. Tayiana Reed votes in favor of the motion</li> <li>Dr. Careen-Joan Franklin votes in favor of the motion</li> <li>Dr. Careen-Joan Franklin votes in favor of the motion</li> <li>Dr. Careen-Joan Franklin votes in favor of the motion</li> <li>Dr. Careen-Joan Franklin votes in favor of the motion</li> <li>Dr. Careen-Joan Franklin votes in favor of the motion</li> <li>Motion carried</li></ul></li></ul></li></ul>	
	<ul> <li>Motion to support the recommendation to require CE training for initial licensing and licensing renewals for providers and dispensers         <ul> <li>Motion carried: Dr. Justin Ortique</li> <li>Motion seconded: Dr. Tayiana Reed</li> <li>Roll call Vote: NO VOTING OCCURED ON THIS MATTER</li> <li>Dr. Justin Ortique withdrew this motion</li> </ul> </li> </ul>	
	<ul> <li>Carla Williams stated that if it's going to be a CE training that it has to come from the boards and be added to the CE requirement for those professions. It should probably be stated as just a training (i.e. remove the CE part) that's required as part of registration for the PDMP program.</li> </ul>	
	<ul> <li>Motion to support the recommendation to require training for initial registration with the PDMP for providers and dispensers.</li> </ul>	

	<ul> <li>Mot</li> <li>Roll</li> <li>Motion of</li> </ul>	<ul> <li>Ms. Camesh</li> <li>Ms. Sheri Di</li> <li>Dr. Sharon F</li> <li>Ms. Kimberle</li> <li>Dr. Tayiana I</li> <li>Dr. Careen-J</li> <li>carried</li> </ul>	Tayiana Ree tique votes in a Thompson v oyle votes in fa lunt votes in fa y Heine votes Reed votes in loan Franklin v	favor of the motion votes in favor of the motion avor of the motion avor of the motion in favor of the motion favor of the motion votes in favor of the motion	
0408-O-05	PDMP Registration	Statistics and C	ompliance R	eport	Dr. Ortique
	Licensed Professional	Number of DC Licensed Active Professionals	Number of Registered PDMP Users	Percentage of DC Licensed Active Professionals Registered with the PDMP	
	Physician	14,787	13,573	91.2%	
	Physician Assistant	1,251	1,136	90.81%	
	Advanced Practice Nurse	4,698	3,995	85.03%	
	Pharmacist	2,066	2,038	98.64%	
	Dentist	1,273	1,163	91.35%	
	Veterinarian	531	472	88.88%	
	Podiatrist	138	125	90.58%	
	Optometrist	212	200	94.48%	
	Naturopathic Physician	65	60	92.30%	
	VA Prescriber		285		
	VA Dispenser		42		
	Pharmacy Technician or Delegate	1,081	4		
	Other (Licensing Board Investigator, Law Enforcement, Medical Examiner, Admin)		33		
	Total	22,727	21,249	91%	
	*Current as of 3/28/2	2025			

2201 Shannon Place SE | 2<sup>nd</sup> Fl, Washington, DC 20002 | E doh.pdmp@dc.gov | https://dchealth.dc.gov/pdmp

All prescription monitoring data collected, maintained, or submitted pursuant to this Program is confidential, privileged, not subject to discovery, subpoena, or other means of legal compulsion in civil litigation, and is not a public record.

0408-0-06		nent and Outre					Dr. Ortiqu	
	<u>Outreach</u>	activities since	the Decen	<u>1ber 2024 me</u>	eeting:			
	Date of Event	Name of Event	Type of Event	Topics Discussed	Audience	Number of Participants		
	1/22/25	DC PDMP Basics for Pharmacists	Webinar	DC PDMP	Pharmaci st	123		
	2/13/25	Management of Opioid Use Disorder Update on Clinical and Regulatory Landscape	Webinar	Opioids	DC Prescriber s and Dispenser s	65		
	C d re o L D w		ing well wi he individu n't include ompliance owe for the essed that participan	th the registr als who have those indivio data look a l ir help with r we had a goo ts. The webi	ation comp the 90 day luals, we're ittle better). egistration o od turnout a nar in Febru	liance. This data y grace period to at about 93% He thanked compliance. at the January Jary had great		
0408-O-07	Presentation: PDMP Updates							
		<ul> <li>Dr. Lowe presented a presentation on PDMP Updates since our last meeting:</li> </ul>						
	<ul> <li>"No Specialty" Provider Notice/Prescriber Reports</li> <li>Reports are sent quarterly</li> <li>Notice to &gt;190 providers was sent on 1/31/2025 to register a "Provider Specialty" to enable receiving Prescriber Reports</li> </ul>							
	<ul> <li>Gateway Integration</li> <li>Streamlines communication and data transfer</li> <li>Providers and dispensers can access PDMP through their EHR or Pharmacy System</li> <li>Last meeting we were at 138 integrations; we're now at 150 integrations. This increase is due to some ads that was ran from December to February on the PDMP website.</li> </ul>							
		<ul> <li>O Interstate D</li> <li>■ DC</li> <li>and</li> </ul>	ata Sharin shares its Military H	PDMP data ealth System		tes, Puerto Rico		
		DA	PDMP has CS to offer		g Education	l University and training for		

	<ul> <li>The first live webinar training was held on 1/22/25. It was titled "DC Prescription Drug Monitoring Program (PDMP) Basics for Pharmacists".</li> <li>Next training is on 4/23/25. Titled "DC Prescription Drug Monitoring Program (PDMP) Basics for Providers'</li> <li>Training focused on PDMP education for Law Enforcement is scheduled for Summer 2025</li> <li>Findings and Recommendations</li> <li>Many prescribers are not aware of the mandatory requirements to query the database and would benefit from formal PDMP training</li> <li>Prescribers can successfully prescribe w/o querying the database, leading to potential in creased patient harm</li> <li>There is currently no method in place to monitor prescriber access history</li> </ul>	
0408-O-08	<ul> <li>Annual Report Draft</li> <li>Plan on having the annual report done by the end of the month. Dr. Ortique expressed that he would like feedback from the committee. The committee will be given two weeks to give their feedback.</li> </ul>	Dr. Ortique
0408-O-09	<ul> <li>Next meeting Dates</li> <li>August 19, 2025</li> <li>December 9, 2025</li> <li><i>The next two meeting will be virtual.</i></li> </ul>	Dr. Ortique
0408-O-10	<ul> <li>Other news/highlights from Committee members</li> <li>Dr. Hunt expressed that there is a lot of information that can be garnered from the PDMP. She expressed that it would be beneficial to have regular reports about certain medications and any other pertinent information</li> <li>Dr. Hunt expressed that the data shared in the January LLDC summit was well received</li> </ul>	
Comments from the Public	No comment from the public	
Motion to Adjourn the Open Session	<ul> <li>Madam Chair, I move that the Committee close the meeting.</li> <li>Motion carried: Dr. Justin Ortique</li> <li>Motion seconded: Dr. Tayiana Reed</li> <li>Roll call Vote: <ul> <li>Dr. Justin Ortique votes in favor of the motion</li> <li>Ms. Sheri Doyle votes in favor of the motion</li> <li>Dr. Sharon Hunt votes in favor of the motion</li> <li>M. Kimberley Heine votes in favor of the motion</li> <li>Dr. Tayiana Reed votes in favor of the motion</li> <li>Dr. Careen-Joan Franklin votes in favor of the motion</li> </ul> </li> <li>Motion carried</li> </ul>	Ms. Nixon

This concludes the meeting. **Meeting Adjourned at 10:49 am** 

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at <u>opengovoffice@dc.gov</u>.